ONCOCLINICAS (ONCO3) Main Indicators
Basic Data - ONCO3
| Company | ONCOCLINICAS |
| Corporate Name | ONCOCLINICAS DO BRASIL SERVICOS MEDICOS S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Exploração de serviços médicos. participação em outras sociedades. nacionais ou estrangeiras. pesquisa e desenvolvimento experimental em ciências físicas e naturais. intermediação em pesquisa clínica. |
| Share | ONCO3 |
| Quote Date | 09/18/2024 |
| Share Type | ON |
| Last Closing | R$ 5.59 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 16.29 M |
| Last Statement | ITR - 06/30/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | IBRA, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 09/19/2024 | |
Relative Prices - ONCO3
| Price/Earnings | 18.94 |
| Price/SBV | 0.96 |
| Price/Net Sales | 0.62 |
| Price/CFO | -11.74 |
| Price/FCF | -5.93 |
| Price/Total Assets | 0.30 |
| Price/EBIT | 4.90 |
| Price/Working Capital | 1.48 |
| Price/NCAV | -0.62 |
| EV/EBIT | 11.66 |
| EV/EBITDA | 8.54 |
| EV/Net Sales | 1.48 |
| EV/CFO | -27.96 |
| EV/FCF | -14.12 |
| EV/Total Assets | 0.72 |
| Company Market Cap | R$ 3.64 B |
| Enterprise Value | R$ 8.67 B |
| Current Financial Statement Date | 06/30/2024 |
| Current Share Price | R$ 5.59 |
| Share Price Date | 09/18/2024 |
| Dividend Yield | 0.00% |
| Updated 09/19/2024 | |
Income Statement - ONCO3
| Net Revenue | R$ 5.86 B |
| Gross Result | R$ 1.99 B |
| EBIT | R$ 743.69 M |
| Depreciation and Amortization | - R$ 271.79 M |
| EBITDA | R$ 1.02 B |
| Net Profit | R$ 192.32 M |
| Net Profit/Share | R$ 0.36 |
| Updated 08/13/2024 | |
| Net Revenue | R$ 1.57 B |
| Gross Result | R$ 526.97 M |
| EBIT | R$ 215.22 M |
| Depreciation and Amortization | - R$ 69.73 M |
| EBITDA | R$ 284.96 M |
| Net Profit | R$ 3.30 M |
| Profit/Share | R$ 0.01 |
| Updated 08/13/2024 | |
Price and Volume Behavior - ONCO3
| Lowest Price 52 weeks | R$ 5.20 |
| Highest Price 52 weeks | R$ 13.00 |
| Variation 2024 | -55.28% |
| Variation 1 year | -51.93% |
| Variation 2 years(total) | -17.55% |
| Variation 2 years(yearly) | -9.16% |
| Variation 3 years(total) | -62.71% |
| Variation 3 years(yearly) | -27.98% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 28.57 M |
| Updated 09/19/2024 | |
Returns and Margins - ONCO3
| Return on Initial Tangible Capital | 18.84% |
| Return on Initial Invested Capital | 9.23% |
| Pre-Tax Return on Initial Tangible Capital | 28.55% |
| Pre-Tax Return on Initial Invested Capital | 13.99% |
| Return on Initial Shareholder´s Equity | 8.62% |
| Return on Initial Asset | 2.25% |
| Gross Margin | 33.98% |
| Net Margin | 3.28% |
| EBIT Margin | 12.69% |
| EBITDA Margin | 17.32% |
| Initial Asset Turnover | 0.69 |
| Financial Leverage | 3.18 |
| Liabilities/Net Worth | 2.18 |
| Net Debt/EBITDA | 4.95 |
| Updated 08/13/2024 | |
Balance Sheet - ONCO3
| Cash and Cash Equivalents | R$ 550.59 M |
| Total Assets | R$ 12.11 B |
| Short-Term Debt | R$ 928.26 M |
| Long-Term Debt | R$ 4.65 B |
| Gross Debt | R$ 5.58 B |
| Net Debt | R$ 5.03 B |
| Shareholder´s Equity | R$ 3.81 B |
| Share Book Value | R$ 7.23 |
| Common Shares | 527,481,598 |
| Preferred Shares | 0 |
| Total | 527,481,598 |
| Common Shares in Treasury | 19,076,007 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 19,076,007 |
| Common Shares (Except Treasury) | 508,405,591 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 508,405,591 |
| Updated 08/13/2024 | |
Cash Flow - ONCO3
| Operating Cash Flow | - R$ 310.23 M |
| Cash Flow from Investments | - R$ 2.13 B |
| Financing Cash Flow | R$ 2.44 B |
| Increase (Reduction) in Cash and Equivalents | R$ 163.00 thousand |
| Updated 08/13/2024 | |
| Operating Cash Flow | - R$ 196.37 M |
| Cash Flow from Investments | - R$ 1.82 B |
| Financing Cash Flow | R$ 2.16 B |
| Increase (Reduction) in Cash and Equivalents | R$ 137.82 M |
| Updated 08/13/2024 | |
Experimental - ONCO3
| CAPEX 3 months | - R$ 76.63 M |
| Free Cash Flow 3 months | - R$ 273.00 M |
| CAPEX 12 months | - R$ 303.86 M |
| Free Cash Flow 12 months | - R$ 614.09 M |
| Updated 08/13/2024 | |